mt1621
Generic: deoxynucleoside-combination substrate enhancement therapy (deoxycytidine and deoxythymidine)
mt1621: developed by 1 company. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ZOGENIX, INC. (ZGNX) | Phase 2 |
Get deeper analysis on mt1621
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis